STOCK TITAN

Seaport Therapeutics (SPTX) director reports existing stock option grants

(Neutral)
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Seaport Therapeutics director Robert J. Hombach reported his holdings of stock options tied to the company’s common stock. He holds options covering 12,258 underlying shares at an exercise price of $10.31 per share that expire on February 23, 2036, and options covering 77,042 underlying shares at $7.39 per share that expire on March 2, 2035.

According to the vesting terms, one grant vests one-third of its underlying shares on March 25, 2026, with the balance vesting in 24 equal monthly installments, while another grant vests in full on February 24, 2027, in each case conditioned on his continued service.

Positive

  • None.

Negative

  • None.
Insider HOMBACH ROBERT J.
Role Director
Type Security Shares Price Value
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 89,300 shares (Direct)
Footnotes (2)
  1. F1. 1/3rd of the shares underlying this option vested and became exercisable on March 25, 2026, with the remaining shares vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
  2. F2. The shares underlying this option shall vest and become exercisable on February 24, 2027, subject to the Reporting Person's continued service on such vesting date.
Option underlying shares 12,258 shares Underlying common stock for option at $10.31 exercise price
Exercise price $10.31 per share Stock option on Seaport Therapeutics common stock
Option expiration February 23, 2036 Expiration date for $10.31 stock option grant
Option underlying shares 77,042 shares Underlying common stock for option at $7.39 exercise price
Exercise price $7.39 per share Second stock option on Seaport Therapeutics common stock
Option expiration March 2, 2035 Expiration date for $7.39 stock option grant
Initial vesting date March 25, 2026 One-third of shares under one option vested on this date
Cliff vesting date February 24, 2027 Second option grant vests and becomes exercisable on this date
Stock Option (Right to Buy) financial
"Security title is reported as "Stock Option (Right to Buy)" with common stock underlying."
underlying security financial
"Each option lists an underlying security title of common stock and underlying shares."
exercise price financial
"The options carry exercise prices of 10.3100 and 7.3900 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"One-third of the shares vested on March 25, 2026, with remaining shares vesting monthly thereafter."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"The stock options have expiration dates in 2035 and 2036 respectively."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Seaport Therapeutics (SPTX) director Robert J. Hombach report in this Form 3?

He reported existing holdings of stock options on Seaport Therapeutics common stock. These options give rights to acquire shares at fixed exercise prices and specified expiration dates, with vesting tied to his continued service on the company’s board over future years.

How many Seaport Therapeutics (SPTX) shares are covered by Robert Hombach’s stock options?

His options cover 12,258 underlying common shares in one grant and 77,042 underlying common shares in another. These figures represent the number of shares he may acquire upon exercising the options, subject to vesting conditions and payment of the stated exercise prices.

What are the exercise prices of Robert Hombach’s Seaport Therapeutics (SPTX) options?

One option grant has an exercise price of $10.31 per share, while the other is priced at $7.39 per share. These exercise prices are the amounts he must pay per share to purchase Seaport Therapeutics common stock if he exercises the respective options.

When do Robert Hombach’s Seaport Therapeutics (SPTX) stock options expire?

One option grant expires on February 23, 2036, and the other expires on March 2, 2035. After these expiration dates, any unexercised portion of the options will lapse, meaning he would no longer have the right to buy those underlying shares.

How do the Seaport Therapeutics (SPTX) options granted to Robert Hombach vest over time?

For one grant, one-third of the underlying shares vested on March 25, 2026, and the remaining two-thirds vest in 24 equal monthly installments. A separate grant is scheduled to vest entirely on February 24, 2027, with both vestings dependent on his continued service.

Does this Seaport Therapeutics (SPTX) Form 3 show any recent stock purchases or sales by Robert Hombach?

The information describes holdings of stock options and their vesting schedules, not open-market share purchases or sales. Transaction summary data indicates no categorized buy or sell transactions, focusing instead on derivative option positions and their terms.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
HOMBACH ROBERT J.

(Last)(First)(Middle)
SEAPORT THERAPEUTICS, INC.
101 SEAPORT BLVD., FLOOR 12

(Street)
BOSTON MASSACHUSETTS 02210

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
04/30/2026
3. Issuer Name and Ticker or Trading Symbol
Seaport Therapeutics, Inc. [ SPTX ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) (1)03/02/2035Common Stock77,042$7.39D
Stock Option (Right to Buy) (2)02/23/2036Common Stock12,258$10.31D
Explanation of Responses:
1. 1/3rd of the shares underlying this option vested and became exercisable on March 25, 2026, with the remaining shares vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
2. The shares underlying this option shall vest and become exercisable on February 24, 2027, subject to the Reporting Person's continued service on such vesting date.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Lana Gladstein, Attorney-in-Fact04/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)